Serum exosomal hsa-let-7f-5p: A potential diagnostic biomarker for metastatic pancreatic cancer detection

Shuai Ren1, Li-Na Song1, Rui Zhao1

  • 1Department of Radiology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.

Abstract

Insights

Serum exosomal microRNAs (miRNAs) show promise for diagnosing metastatic pancreatic cancer. Elevated hsa-let-7f-5p levels in metastatic pancreatic cancer suggest its potential as a non-invasive biomarker.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Exosomal microRNAs (miRNAs) are promising, stable, and accessible biomarkers for cancer diagnosis.
  • The diagnostic utility of serum exosomal miRNAs in metastatic pancreatic cancer is not well-established.

Purpose of the Study:

  • To evaluate the diagnostic potential of serum exosomal miRNAs for detecting metastatic pancreatic cancer.
  • To identify specific exosomal miRNAs that can differentiate metastatic from non-metastatic pancreatic cancer.

Main Methods:

  • Serum exosomes were isolated from 36 pancreatic cancer patients (metastatic and non-metastatic).
  • Exosome characterization involved transmission electron microscopy, nanoparticle tracking analysis, and western blotting.
  • High-throughput sequencing identified differentially expressed miRNAs, with validation via RT-qPCR.

Main Results:

  • Exosomes isolated were confirmed to be of appropriate size and expressed CD63/CD81 markers.
  • 42 differentially expressed exosomal miRNAs were identified between metastatic and non-metastatic groups.
  • Serum exosomal hsa-let-7f-5p was significantly upregulated in metastatic pancreatic cancer (P=0.007) and linked to metastasis-related genes.

Conclusions:

  • Elevated serum exosomal hsa-let-7f-5p is a potential non-invasive biomarker for metastatic pancreatic cancer.
  • This finding aids in distinguishing metastatic from non-metastatic pancreatic cancer.